SciLifeLab The Svedberg seminar series, Alexandra Teleki, Using nanoparticles in healthcare


Monday, March 25

Alexandra Teleki

SciLifeLab Fellow at Uppsala University

Alexandra Teleki is an Assistant Professor and SciLifeLab Fellow in Pharmaceutical Nanotechnology at the Department of Pharmacy, Uppsala University. Her lab develops novel hybrid nanocarrier drug delivery systems that broaden the functionality of state-of-the-art drug formulations to meet the future needs of the healthcare industry in establishing personalized treatment of patients. Thereby, her target is to bridge the gap of innovative (and scalable) nanotechnology research to clinically relevant, patient-compliant diagnosis and treatment. Alexandra received her PhD in Materials Engineering from ETH Zurich and thereafter continued as scientist at DSM Nutritional Products in Basel, Switzerland before she was recruited to Uppsala University. She has received the ETH Medal for outstanding PhD (2008), the DSM Science & Technology Award for outstanding PhD work with a clear future impact (2009), the Smoluchowski Award of the European Aerosol Association (2016) as well as the Sabic Young Professional Award (2016) by the Particle Technology Forum (PTF) of the American Institute of Chemical Engineers (AIChE).

Title: Using nanoparticles in healthcare

A future vision of the healthcare industry is personalized medicine tailored either towards individual needs of patients or to dosage forms optimized for specific patient groups e.g. children and elderly. This requires drug formulation strategies that yield optimal therapy while maintaining high patient compliance; a need that cannot be matched by state-of-the-art drug delivery systems. Classical small drug molecules are today administered orally in tablets or capsules, however with limited functionality and control. Emerging biological therapies mostly rely on systemic administration that not always results in optimal, local therapeutic effects and can be associated with adverse effects. A recent development in pharmaceutical manufacturing is 3D printing that enables on demand production of advanced dosage forms with increased flexibility. In our research we aim to establish a drug delivery platform suitable for 3D printing of personalized dosage forms. The formulation strategy involves colloidal capsules with nanoparticles in their shell. We explore the use of functional nanoparticles in these multiscale structures that are synthesized by flame aerosol technology with proven scalability and reproducibility to ensure a rapid translation to the clinics. In the lecture, I will highlight the use of nanoparticle functionalities that enable bioimaging, triggered drug release by hyperthermia and targeted delivery by functionalization with disease biomarkers.

Host: Pär Matsson